Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ExoHair
- Development stage
- Preclinical
- Lead developer
- Bioscience Institute
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intradermal
01
Overview
ExoHair (EXOHAIR) is an autologous or allogeneic exosome-based therapy developed by Bioscience Institute for hair restoration and the treatment of hair loss, including androgenetic alopecia. The therapy utilizes exosomes derived from adipose-derived mesenchymal stem cells (ADMSCs) that carry bioactive molecules such as proteins, lipids, messenger RNA, and cytokines. These exosomes act as biological messengers to reactivate dormant hair follicles, promote angiogenesis to improve follicular microcirculation, and modulate local immune responses to reduce scalp inflammation. ExoHair is administered via precise scalp microinjections directly to the hair follicles.
- Brand names
- EXOHAIR
Beyond the preview
Go deeper on ExoHair.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ExoHair.